The Tumor-Infiltrating Lymphocytes (TILs) And Cancer Therapy
- Immunotherapy has recently become a major focus for cancer treatment.
- Checkpoint inhibitors have been in the spotlight of these immunotherapies.
- Tumor infiltrating lymphocytes (TILs) is emerging as another promising treatment for cancer.
- Cancer immunotherapy or “Immuno-oncology” has become a highly prioritized area of research and development for the pharmaceutical industry.
- The current data regarding the checkpoint inhibitors is quite remarkable when compared to historical drugs in the same disease indication.
- T cell- immunotherapies are new and represent a an emerging class of drugs that could take a significant steak in the cancer drug industry/market altogether.
There are no Transcripts on LBIO.
Wed, Nov. 12, 5:06 PM
Fri, Jul. 25, 3:05 PM
- Lion Biotechnologies (OTCQB:LBIO -7.1%) enters into a license agreement with the H. Lee Moffitt Cancer Center and Research Institute for exclusive rights to two patent-pending technologies related to methods for improving tumor-infiltrating lymphocytes for adoptive cell therapy. The license applies to all cancers and extends until the expiration of the last patent pertaining to the technologies or 20 years after the effective date of the license agreement.
- The company is developing cancer immunotherapies based on tumor-infiltrating lymphocytes.
- Under the terms of the agreement, Moffitt will receive an upfront licensing fee, development-related milestone payments and low single-digit royalties on commercial sales of products based on the technologies. Specific financial terms are not disclosed.
LBIO vs. ETF Alternatives
Other News & PR